SANTEN, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 1993-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.santeninc.com
Safety and Efficacy Study of DE-110 Ophthalmic Suspension for the Treatment of Dry Eye Disease
Phase 2
Completed
- Conditions
- Dry Eye
- Interventions
- Other: PlaceboDrug: DE-110 ophthalmic suspension low doseDrug: DE-110 ophthalmic suspension high dose
- First Posted Date
- 2010-11-11
- Last Posted Date
- 2014-05-21
- Lead Sponsor
- Santen Inc.
- Target Recruit Count
- 140
- Registration Number
- NCT01239069
Study Assessing Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients
Phase 1
Completed
- Conditions
- Dry Eye
- Interventions
- Drug: DE-101 ophthalmic suspensionDrug: DE-101 ophthalmic suspension vehicle
- First Posted Date
- 2010-05-07
- Last Posted Date
- 2011-11-03
- Lead Sponsor
- Santen Inc.
- Target Recruit Count
- 132
- Registration Number
- NCT01118754
Safety and Efficacy Study of DE-104 Ophthalmic Solution to Treat Open-angle Glaucoma or Ocular Hypertension
Phase 1
Completed
- Conditions
- Open-Angle GlaucomaOcular Hypertension
- Interventions
- Drug: DE-104 medium concentrationDrug: DE-104 high concentrationDrug: Placebo
- First Posted Date
- 2009-03-25
- Last Posted Date
- 2011-11-03
- Lead Sponsor
- Santen Inc.
- Target Recruit Count
- 49
- Registration Number
- NCT00868894
A Dose-Ranging Clinical Study to Assess the Safety and Efficacy of Subconjunctival Injection of Sirolimus in Patients With Dry Eye in the Controlled Adverse Environmental (CAE) Model
- First Posted Date
- 2008-12-25
- Last Posted Date
- 2013-01-10
- Lead Sponsor
- Santen Inc.
- Target Recruit Count
- 143
- Registration Number
- NCT00814944
- Locations
- 🇺🇸
Ophthalmic Research Associates, Andover, Massachusetts, United States
Phase 2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Combination With Lucentis® in Patients With Age-Related Macular Degeneration
Phase 2
Terminated
- Conditions
- Age-Related Macular DegenerationChoroidal Neovascularization
- Interventions
- Drug: Placebo in combination with ranibizumab
- First Posted Date
- 2008-10-03
- Last Posted Date
- 2013-01-10
- Lead Sponsor
- Santen Inc.
- Target Recruit Count
- 62
- Registration Number
- NCT00766337
- Locations
- 🇺🇸
Retinal Consultants of Arizona, Phoenix, Arizona, United States
Ocular Penetration of 1.5% Levofloxacin and 0.5% Moxifloxacin During Corneal Transplant Surgery
Phase 4
Terminated
- Conditions
- Corneal Transplantation
- Interventions
- Drug: 1.5% levofloxacin ophthalmic solutionDrug: 0.5% moxifloxacin ophthalmic solution
- First Posted Date
- 2008-10-02
- Last Posted Date
- 2009-08-26
- Lead Sponsor
- Santen Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT00764582
Phase 1/2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Age-Related Macular Degeneration
Phase 1
Terminated
- Conditions
- Choroidal NeovascularizationAge-related Macular Degeneration
- Interventions
- First Posted Date
- 2008-07-10
- Last Posted Date
- 2013-01-10
- Lead Sponsor
- Santen Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT00712491
- Locations
- 🇺🇸
Retinal Consultants of Arizona, Phoenix, Arizona, United States
Ocular Availability in Human Tears After Topical Administration of 1.5% Levofloxacin Compared to Active Comparators
Phase 4
Completed
- Conditions
- Healthy
- Interventions
- Drug: 1.5% levofloxacin ophthalmic solutionDrug: 0.3% gatifloxacin ophthalmic solutionDrug: 0.5% moxifloxacin hydrochloride ophthalmic solution
- First Posted Date
- 2008-06-23
- Last Posted Date
- 2009-02-06
- Lead Sponsor
- Santen Inc.
- Target Recruit Count
- 72
- Registration Number
- NCT00703313
- Locations
- 🇺🇸
Vistakon, Jacksonville, Florida, United States
Dose Ranging Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Diabetic Macular Edema
- First Posted Date
- 2008-04-11
- Last Posted Date
- 2013-01-10
- Lead Sponsor
- Santen Inc.
- Target Recruit Count
- 131
- Registration Number
- NCT00656643
- Locations
- 🇺🇸
Retinal Consultants of Arizona, Phoenix, Arizona, United States
Safety and Efficacy Study of DE-104 Ophthalmic Solution to Treat Open-angle Glaucoma or Ocular Hypertension
Phase 2
Completed
- Conditions
- Open-Angle GlaucomaOcular Hypertension
- Interventions
- Drug: DE-104 ophthalmic solution, low concentrationDrug: DE-104 ophthalmic solution, medium concentrationDrug: DE-104 ophthalmic solution, high concentrationDrug: Placebo
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2011-11-03
- Lead Sponsor
- Santen Inc.
- Target Recruit Count
- 165
- Registration Number
- NCT00650338
- Locations
- 🇺🇸
Associated Glaucoma Consultants, Philadelphia, Pennsylvania, United States
🇺🇸Sall Research Medical Center, Artesia, California, United States
🇺🇸University of Nebraska Medical Center, Omaha, Nebraska, United States
© Copyright 2025. All Rights Reserved by MedPath